Klin Onkol 1996; 9(4): 130-134.
Summary: The authors in this study are continuing in their long term experience in the treatment of multiple myeloma by polychemo-therapy according to protocol VMCP/MOCCA. Since 1990 a randomised group was created - only chemotherapy was given in the first group of 96 patients, in the second one chemotherapy combined with proteolytical enzymes was used (Wobe Mugos). The enzymes are the biological response modifiers, and as shown in the frequency and survival curves, the medial survival has lengthtened from 20 to 47 months. The prolongation of survival is significant in the stage II patients and can be explained by tumor mass reduction, decrease of cytokine activity, but mostly by decrease of infectious complications. The laboratory tests have shown a significant decrease of B2M, serum soluble TNF receptors and a decrease of the cellular membrane receptor density (CD38, Integrins, CD44, CD54, CD56). The overall survival of 198 patients in the chemotherapy group is more than 71 months and in the immunochemotherapy more than 85 months in 70% of patients in follow up.
